Table 2 Unadjusted and adjusted hazard ratios for recurrence within five years in intestinal and pancreatobiliary type tumours
Intestinal type | Pancreatobiliary type | |||||
|---|---|---|---|---|---|---|
Unadjusted | Adjusted | Unadjusted | Adjusted | |||
n(events) | HR(95%CI) | HR(95%CI) | n(events) | HR(95%CI) | HR(95%CI) | |
Age | ||||||
Continuous | 61 (29) | 1.00 (0.96–1.03) | 1.07 (1.02–1.13) | 106 (88) | 0.98 (0.96–1.01) | 1.00 (0.96–1.03) |
Gender | ||||||
Female | 34 (11) | 1.00 | 1.00 | 50 (42) | 1.00 | 1.00 |
Male | 27 (18) | 2.31 (1.08–4.94) | 2.40 (0.94–6.14) | 56 (46) | 1.06 (0.70–1.61) | 0.88 (0.53–1.49) |
Tumour origin | ||||||
Duodenum | 13 (4) | 1.00 | 1.00 | _ | _ | |
Ampulla-Intestinal type | 48 (25) | 2.18 (0.76–6.27) | 6.82 (1.32–35.12) | _ | _ | |
Ampulla-Pancreatobiliary type | _ | _ | 19 (16) | 1.00 | 1.00 | |
Distal Bile duct | _ | _ | 44 (38) | 1.10 (0.61–1.98) | 1.52 (0.78–2.94) | |
Pancreas | _ | _ | 43 (34) | 1.06 (0.58–1.93) | 0.93 (0.49–1.77) | |
Tumour size | ||||||
Continuous | 61 (30) | 1.00 (0.98–1.02) | 1.04 (1.00–1.09) | 106 (88) | 1.03 (1.02–1.05) | 1.02 (0.99–1.04) |
T-stage | ||||||
T1 | 4 (1) | 1.00 | 1.00 | 2 (1) | 1.00 | 1.00 |
T2 | 10(3) | 1.28 (0.13–12.30) | 3.71 (0.34–40.64) | 10 (6) | 1.61 (0.19–13.36) | 0.66 (0.07–6.08) |
T3 | 25 (9) | 1.86 (0.24–14.71) | 5.72 (0.50–65.06) | 77 (66) | 4.67 (0.64–33.96) | 1.21 (0.15–9.92) |
T4 | 22 (16) | 5.44 (0.72–41.21) | 6.36 (0.21–195.20) | 17 (15) | 4.31 (0.56–33.10) | 1.83 (0.08–40.27) |
N-stage | ||||||
N0 | 33 (11) | 1.00 | 1.00 | 29 (21) | 1.00 | 1.00 |
N1 (metastasis in 1–3 lgl) | 19 (11) | 2.07 (0.90–4.78) | 1.00 (0.37–2.70) | 45 (37) | 2.17 (1.25–3.78) | 2.04 (1.13–3.67) |
N2 (metastasis in 4 or more lgl) | 9 (7) | 4.06 (1.55–10.59) | 6.88 (1.81–26.15) | 32 (30) | 3.11 (1.72–5.61) | 2.61 (1.42–4.83) |
Differentiation grade | ||||||
Well-moderate | 30 (11) | 1.00 | 1.00 | 39 (29) | 1.00 | 1.00 |
Poor | 31 (18) | 2.16 (1.02–4.57) | 1.38 (0.40–4.79) | 67 (59) | 2.32 (1.45–3.71) | 2.02 (1.20–3.39) |
Involved margins, status | ||||||
R0 | 17 (3) | 1.00 | 1.00 | 6 (4) | 1.00 | 1.00 |
R1 & Rx | 44 (26) | 4.51 (1.36–14.94) | 2.23 (0.62–8.03) | 100 (84) | 2.31 (0.84–6.36) | 2.39 (0.84–6.76) |
Lymphatic growth | ||||||
Absent | 28 (5) | 1.00 | 1.00 | 32 (23) | 1.00 | 1.00 |
Present | 33 (24) | 6.16 (2.34–16.19) | 6.19 (1.76–21.82) | 74 (65) | 1.77 (1.09–2.88) | 1.05 (0.59–1.85) |
Vascular growth | ||||||
Absent | 56 (24) | 1.00 | 1.00 | 70 (55) | 1.00 | 1.00 |
Present | 5 (5) | 8.16 (2.86–23.30) | 1.62 (0.39–6.65) | 36 (33) | 2.30 (1.47–3.61) | 2.08 (1.28–3.36) |
Perineural growth | ||||||
Absent | 42 (15) | 1.00 | 1.00 | 22 (14) | 1.00 | 1.00 |
Present | 19 (14) | 2.72 (1.31–5.66) | 1.01 (0.27–3.81) | 84 (74) | 2.93 (1.57–5.46) | 2.04 (1.06–3.90) |
Growth in peripancreatic fat | ||||||
Absent | 40 (12) | 1.00 | 1.00 | 22 (13) | 1.00 | 1.00 |
Present | 21 (17) | 4.74 (2.23–10.10) | 3.60 (1.43–9.07) | 84 (75) | 2.60 (1.42–4.75) | 1.45 (0.76–2.77) |
Adjuvant treatment | ||||||
No | 43 (21) | 1.00 | 1.00 | 49 (40) | 1.00 | 1.00 |
Yes | 18 (8) | 0.87 (0.38–1.96) | 0.12 (0.04–0.44) | 57 (48) | 1.08 (0.70–1.65) | 0.89 (0.54–1.49) |
PODXL expression | ||||||
Non-membranous | 49 (20) | 1.00 | 1.00 | 51 (40) | 1.00 | 1.00 |
Membranous | 12 (9) | 2.44 (1.10–5.44) | 5.12 (1.43–18.31) | 55 (88) | 1.63 (1.07–2.49) | 1.53 (0.99–2.38) |